After parting ways with its diabetes franchise nearly three years ago, BD is slimming down even further with a plan to divest its diagnostic and biosciences businesses as the company nears the finish ...
BD’s new MiniDraw diagnostic devices could let pharmacists—and, one day, maybe patients—manage blood testing needs and monitor health conditions. BD received its FDA authorizations for two blood draw ...
Medical technology company Becton, Dickinson and Company (NYSE:BDX) announced better-than-expected revenue in Q1 CY2026, with sales up 5.2% year on year to $4.71 billion. Its non-GAAP profit of $2.90 ...
Global medtech giant BD (Becton, Dickinson and Co.) announced today it has acquired Tepha Inc., a developer and manufacturer of proprietary resorbable polymer technology. Tepha's resorbable polymer ...
Becton Dickinson & Co. is set to make additional investments in its U.S. manufacturing network to add capacity for critical medical devices. “BD has a longstanding history as a leading U.S.
Hosted on MSN
BD’s (NYSE:BDX) Q1 CY2026 sales beat estimates
Medical technology company Becton, Dickinson and Company (NYSE:BDX) announced in Q1 CY2026, with sales up 5.2% year on year to $4.71 billion. Its non-GAAP profit of $2.90 per share was 4.5% above ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results